To evaluate CLDN18.2-CD3 bispecific and CLDN18.2 ADC efficacy in vivo, we developed PDX models, utilizing patient-derived tumor blocks and activated human T cells in immune-compromised NSG mice. This evidence concerns the gene CLDN18 and neoplasm.